Want to see JP:6090 full AI Analyst Report?
6090 Stock Chart & Stats
¥715.00
¥1.00(0.16%)
At close: 4:00 PM EST
¥715.00
¥1.00(0.16%)
Day’s Range― - ―
52-Week Range¥581.00 - ¥797.00
Previous CloseN/A
Volume5.70K
Average Volume (3M)10.25K
Market Cap
¥3.63B
Enterprise Value¥2.32B
Total Cash (Recent Filing)¥1.59B
Total Debt (Recent Filing)¥110.47M
Price to Earnings (P/E)28.5
Beta0.31
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.35%
Share Statistics
EPS (TTM)43.61
Shares Outstanding5,919,797
10 Day Avg. Volume8,100
30 Day Avg. Volume10,250
Financial Highlights & Ratios
PEG Ratio2.95
Price to Book (P/B)2.36
Price to Sales (P/S)3.09
P/FCF Ratio19.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a strong equity base provide durable financial flexibility. A 0.058 debt/equity and 13.42% ROE mean the company can fund R&D, absorb cyclical downturns, and pursue selective investments without stretching liquidity, supporting strategic resilience.
High And Sustainable MarginsSustained gross margins >60% and mid-teens net margins reflect a differentiated, high-value analytical services model with pricing power. These margins enable reinvestment in capabilities, support profitability even with modest revenue growth, and underpin long-term cash generation.
Solid Free Cash Flow GenerationHealthy FCF relative to earnings indicates the business converts profits into cash, enabling capex and working capital funding without heavy external financing. This cash conversion supports sustainable operations, shareholder returns, and strategic investments over the medium term.
Bears Say
Declining RevenueMaterial negative top-line growth over recent periods signals structural demand or commercial execution issues. Persistent revenue decline limits scale economies, constrains R&D payback, and makes it harder to leverage healthy margins into absolute profit and cash expansion over the next several quarters.
Earnings DeteriorationA steep EPS contraction suggests operating or one-off pressures that materially reduced earnings power. Large EPS declines reduce internal funding capacity, strain dividend sustainability or reinvestment plans, and indicate vulnerability if revenue headwinds persist.
Limited Scale / Small HeadcountA small workforce implies constrained capacity to scale commercial outreach, broaden service lines, or handle large enterprise contracts. Limited scale raises client concentration and execution risk, slowing market penetration and making sustained top-line recovery more challenging.
Human Metabolome Technologies, Inc. News
6090 FAQ
What was Human Metabolome Technologies, Inc.’s price range in the past 12 months?
Human Metabolome Technologies, Inc. lowest stock price was ¥581.00 and its highest was ¥797.00 in the past 12 months.
What is Human Metabolome Technologies, Inc.’s market cap?
Human Metabolome Technologies, Inc.’s market cap is ¥3.63B.
When is Human Metabolome Technologies, Inc.’s upcoming earnings report date?
Human Metabolome Technologies, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 36 days.
How were Human Metabolome Technologies, Inc.’s earnings last quarter?
Human Metabolome Technologies, Inc. released its earnings results on May 13, 2026. The company reported ¥21.61 earnings per share for the quarter, beating the consensus estimate of N/A by ¥21.61.
Is Human Metabolome Technologies, Inc. overvalued?
According to Wall Street analysts Human Metabolome Technologies, Inc.’s price is currently Overvalued.
Does Human Metabolome Technologies, Inc. pay dividends?
Human Metabolome Technologies, Inc. pays a Annually dividend of ¥18 which represents an annual dividend yield of 2.35%. See more information on Human Metabolome Technologies, Inc. dividends here
What is Human Metabolome Technologies, Inc.’s EPS estimate?
Human Metabolome Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Human Metabolome Technologies, Inc. have?
Human Metabolome Technologies, Inc. has 5,919,797 shares outstanding.
What happened to Human Metabolome Technologies, Inc.’s price movement after its last earnings report?
Human Metabolome Technologies, Inc. reported an EPS of ¥21.61 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.147%.
Which hedge fund is a major shareholder of Human Metabolome Technologies, Inc.?
Currently, no hedge funds are holding shares in JP:6090
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Technical Analysis
BML
―
Shin Nippon Biomedical Laboratories, Ltd.
―
Cosmo Bio Co., Ltd.
―
―
Perseus Proteomics, Inc.
―